{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:16:21Z","timestamp":1786119381452,"version":"build-2736575974"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"34","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1097\/md.0000000000004126","type":"journal-article","created":{"date-parts":[[2016,8,25]],"date-time":"2016-08-25T11:51:53Z","timestamp":1472125913000},"page":"e4126","source":"Crossref","is-referenced-by-count":17,"title":["Impacts of 12-dose regimen for latent tuberculosis infection"],"prefix":"10.1097","volume":"95","author":[{"given":"Yi-Wen","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun-Fa","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Po","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas Chang-Yao","family":"Tsao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Ming","family":"Tsao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-17-20210226","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s13665-013-0064-y","article-title":"Diagnosis and treatment of latent tuberculosis infection: an update","volume":"2","author":"Person","year":"2013","journal-title":"Curr Respir Care Rep"},{"key":"R2-17-20210226","first-page":"879","article-title":"Identification and management of latent tuberculosis infection","volume":"79","author":"Hauck","year":"2009","journal-title":"Am Fam Physician"},{"key":"R3-17-20210226","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1128\/MMBR.00010-14","article-title":"Latent tuberculosis infection: myths, models, and molecular mechanisms","volume":"78","author":"Dutta","year":"2014","journal-title":"Microbiol Mol Biol Rev"},{"key":"R4-17-20210226","first-page":"S221","article-title":"This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement.","volume":"161","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"R5-17-20210226","doi-asserted-by":"crossref","first-page":"768","DOI":"10.5588\/ijtld.11.0302","article-title":"Is isoniazid for 6 months more cost-effective than isoniazid for 9 months?","volume":"16","author":"Pina","year":"2012","journal-title":"Int J Tuberc Lung Dis"},{"key":"R6-17-20210226","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/j.1440-1843.2010.01751.x","article-title":"Treatment of latent tuberculosis infection: an update","volume":"15","author":"Lobue","year":"2010","journal-title":"Respirology"},{"key":"R7-17-20210226","first-page":"1","article-title":"Targeted tuberculin testing and treatment of latent tuberculosis infection.","volume":"49","year":"2000","journal-title":"MMWR Recomm Rep"},{"key":"R8-17-20210226","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1183\/09031936.00079310","article-title":"Treatment of latent infection with Mycobacterium tuberculosis: update 2010","volume":"37","author":"Leung","year":"2011","journal-title":"Eur Respir J"},{"key":"R9-17-20210226","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","article-title":"Three months of rifapentine and isoniazid for latent tuberculosis infection","volume":"365","author":"Sterling","year":"2011","journal-title":"N Engl J Med"},{"key":"R10-17-20210226","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1056\/NEJMc1200489","article-title":"Rifapentine and isoniazid for latent tuberculosis","volume":"366","author":"Mirsaeidi","year":"2012","journal-title":"N Engl J Med"},{"key":"R11-17-20210226","doi-asserted-by":"crossref","first-page":"419","DOI":"10.7326\/M14-1019","article-title":"Treatment of latent tuberculosis infection: a network meta-analysis","volume":"161","author":"Stagg","year":"2014","journal-title":"Ann Intern Med"},{"key":"R12-17-20210226","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.5588\/ijtld.13.0423","article-title":"Cost-effectiveness of a 12-dose regimen for treating latent tuberculous infection in the United States","volume":"17","author":"Shepardson","year":"2013","journal-title":"Int J Tuberc Lung Dis"},{"key":"R13-17-20210226","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jinf.2005.08.008","article-title":"Mycobacterium tuberculosis in Taiwan","volume":"52","author":"Hsueh","year":"2006","journal-title":"J Infect"},{"key":"R14-17-20210226","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1017\/S0950268897007917","article-title":"The natuaral history of tuberculosis: the implicaitons of age-dependent risks of disease and the role of reinfection","volume":"119","author":"Vynnycky","year":"1997","journal-title":"Epidemiol Infect"},{"key":"R16-17-20210226","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1111\/j.1469-0691.2010.03331.x","article-title":"Understanding cost-effectiveness","volume":"16","author":"Zilberberg","year":"2010","journal-title":"Clin Microbiol Infect"},{"key":"R17-17-20210226","doi-asserted-by":"crossref","first-page":"751","DOI":"10.5588\/ijtld.14.0052","article-title":"Update on cost-effectiveness of a 12-dose regimen for latent tuberculous infection at new rifapentine prices","volume":"18","author":"Shepardson","year":"2014","journal-title":"Int J Tuberc Lung Dis"},{"key":"R18-17-20210226","doi-asserted-by":"crossref","first-page":"e110104","DOI":"10.1371\/journal.pone.0110104","article-title":"Gender disparities in latent tuberculosis infection in high-risk individuals: a cross-sectional study","volume":"9","author":"Ting","year":"2014","journal-title":"PLoS One"},{"key":"R19-17-20210226","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2147\/TCRM.S1458","article-title":"Factors affecting therapeutic compliance: a review from the patient's perspective","volume":"4","author":"Jin","year":"2008","journal-title":"Ther Clin Risk Manag"},{"key":"R20-17-20210226","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/j.1440-1843.2006.00941.x","article-title":"antituberculosis drugs and hepatotoxicity","volume":"11","author":"Yew","year":"2006","journal-title":"Respirology"},{"key":"R21-17-20210226","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.rmed.2013.01.017","article-title":"Cost-effectiveness of rifampin for 4 months and isoniazid for 6 months in the treatment of tuberculosis infection","volume":"107","author":"Pina","year":"2013","journal-title":"Respir Med"},{"key":"R22-17-20210226","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s10096-012-1788-2","article-title":"Cost-effectiveness of rifampin for 4 months and isoniazid for 9 months in the treatment of tuberculosis infection","volume":"32","author":"Pina","year":"2013","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"R23-17-20210226","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1164\/rccm.200901-0153OC","article-title":"Costs and cost-effectiveness of four treatment regimens for latent tuberculosis infection","volume":"179","author":"Holland","year":"2009","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000004126","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:10:02Z","timestamp":1786039802000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00005792-201608230-00017"}},"subtitle":["Treatment completion rate and cost-effectiveness in Taiwan"],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":22,"journal-issue":{"issue":"34","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000004126","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]}}}